Motilal Oswal reveals Buy and Hold ratings for May 30, 2025. Key picks include Ajanta Pharma, Ceat, and Varun Beverages. Full breakdown inside.
Motilal Oswal Releases New Stock Recommendations for May 30, 2025
Mumbai, May 30, 2025 – In its latest report, leading brokerage house Motilal Oswal shared fresh insights on a range of Indian stocks across multiple sectors. With a mix of Buy and Hold recommendations, the report helps investors align their portfolio strategies with current market conditions.
Below is a summary of the top recommendations, including current price, target price, expected return, and investment stance.
🔷 Top Buy Recommendations
Ajanta Pharma
- Current Price: ₹2,594.25
- Target Price: ₹3,260.00
- Potential Gain: 25.66%
- Recommendation: Buy
- Full PDF
Varun Beverages
- Current Price: ₹510.40
- Target Price: ₹665.00
- Potential Gain: 30.29%
- Recommendation: Buy
- Full PDF
Five-Star Business Finance
- Current Price: ₹679.10
- Target Price: ₹840.00
- Potential Gain: 23.69%
- Recommendation: Buy
📄 View Report
Star Health & Allied Insurance
- Current Price: ₹416.05
- Target Price: ₹460.00
- Potential Gain: 10.56%
- Recommendation: Buy
- Full PDF
JSW Infrastructure
- Current Price: ₹298.10
- Target Price: ₹370.00
- Potential Gain: 24.12%
- Recommendation: Buy
- Full PDF
Ceat and UTI Asset Management Co. have also been marked as “Target Met”, signaling that prior bullish calls were accurate and timely.
📄 Ceat Full PDF
📄 UTI Full PDF
🔷 Hold Recommendations
Shoppers Stop
- Current Price: ₹519.25
- Target Price: ₹500.00
- Potential Return: -3.71%
- Recommendation: Hold
- Full PDF
Bajaj Finance
- Current Price: ₹9,206.70
- Target Price: ₹10,000.00
- Potential Gain: 8.62%
- Recommendation: Hold
- Full PDF
Summary
Motilal Oswal’s May 30, 2025 stock advisory reflects a positive stance on high-performing sectors including finance, healthcare, and FMCG. Notably, stocks like Varun Beverages and Ajanta Pharma offer over 25% potential upside. Meanwhile, Hold ratings on Shoppers Stop and Bajaj Finance indicate a more cautious outlook. These recommendations provide investors with a well-rounded view of mid-term equity opportunities.
